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ABSTRACT OF THE DISSERTATION 
 
Role of IGF-II, PRL, and FABPs in the Breast Cancer Disparity 
among AA Women 
 
by 
Teleka Cassandra Patrick 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, June 2013 
Dr. Daisy D. De Leόn, Chairperson 
 
It is well documented that African-American (AA) patients present with more 
advanced states of breast cancer and have lower survival rates than Caucasian-Americans 
(CA).  Epidemiological data have shown that pregnancy and lactation at an early age in 
humans reduce the risk of breast cancer.  Studies in mice and rats have shown that 
lactation stimulates the expression of intracellular fatty-acid binding protein 3 (FABP3).  
FABP3 is detected in human breast tissue and is known as mammary-derived growth 
inhibitor (MDGI) because it has a strong inhibitory effect on cell proliferation.  FABP5 is 
also expressed in the breast, and has been associated with metastasis and angiogenesis.  
Thus we hypothesized that increased expression of FABP3 and decreased expression of 
FABP5 in the normal breast would be associated with protection against carcinogenesis, 
and that these changes would be regulated by prolactin (PRL) and IGF-II, which are 
major mediators of breast differentiation.  We also hypothesized that differential 
expression of these FABPs could provide insight into the breast cancer health disparity, 
particularly since AA women have lower lactation rates relative to CA women.  
Therefore, we assessed the expression of these FABPs in paired normal/tumor breast 
cancer tissues from AA and CA, and used AA and CA-derived cell lines to characterize 
xi 
potential regulatory mechanisms involving PRL and IGF-II.  Our studies have provided 
much needed information about the mechanisms involved in the protective effect 
lactation induces in the breast, and potentially offer new tools to prevent breast cancer. 
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CHAPTER ONE 
INTRODUCTION 
 
Breast cancer is the number one cancer affecting women, taking first place in 
incidence, and second only to lung cancer in mortality.  Recently, health disparities 
between African-American (AA) and Caucasian-American (CA) breast cancer 
patients have emerged.  AA and Hispanic patients present with more advanced stages of 
breast cancer and have lower survival rates than CA patients [Li et al., 2003].  
Some of this disparity may be due to socioeconomic factors [Adams et al., 
2009].  In other cases, certain therapies, such as cancer-directed surgery for invasive 
breast cancer or radiation therapy, are recommended to AA women less frequently 
[Shavers et al., 2003].  Apart from socioeconomic factors, however, there may be 
demonstrable biological differences between AA and CA patients, as demonstrated in a 
recent study.  Yancy and coworkers [2007] discovered that there were five metastasis-
related genes (Atp1b1, CARD 10, KLF4, Spint2, Acly) whose expression significantly 
differed between AA and CA breast cancer cell lines.  One of these genes, Acly, 
plays a critical role in fatty acid biosynthesis.  Differences in levels of fatty acid 
binding proteins (FABPs) may be yet another biological factor, which may help to 
explain the differences in breast cancer presentation and survival between AA and CA 
patients.  
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Role of Fatty Acid-Binding Proteins in the Cell 
Intracellular fatty acid-binding proteins (FABPs) are about 15 kDa in size, and are 
encoded by multiple genes.  FABPs bind to and increase the solubility of long chain 
fatty acids (LCFAs) and other hydrophobic ligands.  High levels of unbound long-
chain fatty acids have adverse effects on the cell, including increased reactive oxygen 
species production due to mitochondrial uncoupling and inhibition of electron transport 
within the respiratory chain [Glatz and van der Vusse, 1996; Zimmerman and Veerkamp, 
2002; Schonfeld and Wojtczak, 2008].  As shown in Figure 1, FABPs transport LCFAs 
from the plasma membrane to various sites of fatty acid oxidation, to sites of fatty 
acid esterification into triacylglycerols or phospholipids, to cytosolic or membrane-
bound proteins for metabolic activation, or to the nucleus, to promote 
transcription of genes by binding nuclear receptors [Hertzel and Bernlohr, 2000; 
Zimmerman and Veerkamp, 2002; Coe and Bernlohr, 1998].  LCFAs bind to peroxisome 
proliferator-activated receptors (PPARs) α, β/δ, and γ, while acyl CoA-modified LCFAs 
(LCFA-CoAs) bind to the PPARs as well as to hepatocyte nuclear receptor-4α [Schroeder 
et al., 2008].  In this dissertation, we will focus on FABP3 and FABP5, because FABP3 
is highly expressed in differentiated mammary tissue, and FABP5 has been shown to 
be upregulated in pathologic states in various tissues [De León et al., 1996].  The role 
of FABPs in binding hydrophobic ligands is very critical. Unbound LCFAs may have 
adverse effects on the cell, such as disturbance of membrane structure and function, 
inhibition of enzymes, modulation of receptor binding, activation of soluble protein 
kinase C, activation of brown adipose tissue uncoupling protein, and impairment of ion 
channels [Glatz and van der Vusse, 1996; Zimmerman and Veerkamp, 2002]. 
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Figure 1. Cellular Function of Fatty Acid-Binding Proteins.  FABPs have several 
roles within the cell, including transporting fatty acids to the nucleus to regulate 
transcription of target genes. From Furuhashi M and Hotamisligil GS, 2008, Fatty 
acid-binding proteins: role in metabolic diseases and potential as drug targets, Nat 
Rev Drug Discov, 7(6), 489-503. 
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FABP3 Associated with Protection Against Carcinogenesis 
FABP3 is also known as mammary derived growth inhibitor (MDGI).  It is the 
most widely distributed of the FABPs, and is expressed in heart, skeletal and smooth 
muscle, mammary epithelial cells, aorta, distal tubules of the kidney, lung, brain, 
placenta, and ovary [Zimmerman and Veerkamp, 2002].  FABP3 is known to 
signal through the nuclear receptor PPARα [Schroeder et al., 2008] by 
transporting long chain fatty acids to this receptor.  Omega-3 fatty acids, which 
are known to exert antitumor effects, bind to PPARα [Bocca et al., 2008].  
PPARα activation has been shown to inhibit tumor growth and angiogenesis in 
malignant mammary epithelial cells, by enhancing the binding of hypoxia 
inducible factor 1α (HIF1α) to von Hippel-Lindau tumor suppressor (pVHL).  
pVHL then causes degradation of HIF-1α through the ubiquitin-proteasome 
pathway [Zhou et al., 2012], which decreases secretion of vascular endothelial 
growth factor (VEGF), and inhibits tube formation by endothelial cells.  The tube 
formation assay, which looks at the ability of endothelial cells to form tubes on a 
gelled basement membrane matrix, is considered to be an in vitro assay of 
angiogenesis [Arnaoutova and Kleinman, 2010].  Thus, FABP3 signaling in the 
nucleus results in inhibition of angiogenesis, which limits metastasis.  Apart from 
nuclear signaling, FABP3 also binds to integrin α-subunits within the cell to 
inhibit integrin activity, thus reducing integrin adhesion to type I collagen and 
fibronectin, and inhibiting cell migration and invasion [Nevo et al., 2010]. 
Pregnancy and lactation before the age of 24 has been shown to be protective 
against breast cancer [Russo et al., 2005], and the induction of FABP3 expression in the 
6 
breast may help to explain this.  According to Russo and coworkers, pregnancy and 
lactation stimulate the stem cells (“Stem Cells 1”) of Lobule 1, which is the cell 
population that is left after menopause, to differentiate and to express a different 
genomic signature (“Stem cells 2”).  “Stem cells 1” highly express estrogen receptor 
I, IGF-II receptor, IGF binding proteins 4 and 7, and progesterone receptor.  “Stem cells 
2” highly express a different set of proteins, including FABP3 and are thought to be 
refractory to carcinogenesis [Russo et al., 2005].  Studies indicate that AA women 
have lower breastfeeding rates compared to all other ethnic groups, and therefore the 
induction of FABP3 expression may not be as significant as in CA women [Bentley et 
al., 2003].  This difference in lactation rates may be due to lack of education regarding 
the positive benefits of breastfeeding for mother and child, cultural norms, and 
individual beliefs [Ibid.].  FABP3 has been shown to regulate growth of normal mouse 
mammary epithelial cells, to promote normal mammary gland differentiation, and 
stimulate milk protein synthesis [Yang et al., 1994; Specht et al., 1996; Borchers et al., 
1997].  In breast cancer tissues, levels of FABP3 are downregulated [Hertzel and 
Bernlohr, 2000], and the gene may even be silenced in many human breast cancers 
[Huynh et al., 1996].  FABP3 has a well-demonstrated tumor-suppressing role: 
when the gene is introduced into MCF-7 breast cancer cells, they exhibit 
characteristics of more differentiated cells [Borchers et al., 1997; Huynh and Beamer, 
2008].   
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FABP5 Associated with Tumor Aggressiveness 
FABP5 is also expressed in multiple tissues.  It can be found in skin, lens, 
adipose tissues, endothelial cells, lung, mammary cells, stomach, tongue 
(especially stratified epithelia), stratified epithelia of epidermis, stomach, placenta, 
heart, brain, liver, spleen, skeletal muscle, intestine, testis, urothelium, and retina 
[Hertzel and Bernlohr, 2000].  In nerve cells FABP5 has been shown to be involved in 
stress response and regulation of neurite growth and neuronal differentiation [De León et 
al., 1996; Liu et al., 2008; Allen et al., 2000; Allen et al., 2001].  Similarly to FABP3, 
FABP5 binds to long chain polyunsaturated fatty acids and translocates them to the 
nucleus, to bind to PPARβ/δ.  This then causes upregulation of VEGF [Kannan-
Thulasiraman et al., 2010; Schug et al., 2007].  VEGF is overexpressed in a significant 
percentage of breast tumors, and this expression has been associated with a worse 
prognosis in patients with invasive breast disease [Bajo et al., 2004; Heffelfinger et al., 
1999; Gieseler et al., 2007].  FABP5 also competes with cellular retinoic acid binding 
protein 2 (CRABP-2) for retinoic acid.  FABP5 binds retinoic acid, keeping it in the 
cytoplasm and preventing it from being translocated to the nucleus by CRABP-2, thus 
inhibiting tumor growth [Liu et al., 2011].  
FABP5 has been shown to be upregulated in a number of altered states with 
disturbed lipid profiles.  The gene has been shown to induce metastasis, and the levels 
of mRNA are 6.5-fold higher in malignant breast cell lines compared to Huma 121 
benign lines [Jing et al., 2000].  A high correlation has been demonstrated between 
elevated FABP5 mRNA and protein levels and estrogen receptor/progesterone receptor-
negative status, high tumor grade, and poor prognosis [Liu et al., 2011].  Another study 
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by Hammamieh and colleagues [2005] demonstrated that FABP5 levels were decreased 
in malignant breast cell lines compared to normal human mammary epithelial cells.  
Within tissues, FABPs have a compensatory relationship.  For example, in FABP5-
gene knockout mice, FABP3 was elevated in the liver [Owada et al., 2002] and in 
FABP4 (adipocyte type)- knockout mice, FABP5 mRNA was upregulated in adipocytes 
20- to 40-fold [Hertzel and Bernlohr, 2000].  Therefore, it is reasonable to believe 
that levels of FABP5 would be increased in the breast cancer state, since levels of 
FABP3 are decreased.  
 
Significance of Studying FABP Levels in Breast Tissues 
The literature describing differential expression of FABPs in benign and 
malignant breast tissues/cells is very scarce.  Additionally, levels of FABPs 3 and 5 
have not been specifically measured in AA and CA tissues/cell lines.  Therefore, 
measuring the levels of FABPs 3 and 5 in normal and malignant tissues from AA and CA 
women, and in normal and malignant cell lines established from AA and CA women, will 
add to this body of literature.  Establishing differential expression between these ethnic 
groups may help to elucidate the breast cancer health disparity.  For example, if FABP3 
is significantly lower in AA normal tissues compared to CA normal tissues/cell lines due 
to decreased lactation and induction of FABP3 expression in the former, this may 
indicate a lack of protection against cancer in normal AA breast tissue.  Furthermore, we 
will be able to determine if the patterns of expression differ among age groups (ages 
below 50, and ages 50 and older), and if certain age groups may be at higher risk for 
breast cancer, based on FABP3 expression, relative to other age groups.  
 
9 
Role of IGF-II in Normal Breast Differentiation and in 
Carcinogenesis 
The expression of FABP3 and FABP5 may be mediated through insulin 
growth factor II (IGF-II).  PRL regulation of IGF-II mRNA has been demonstrated, 
and since PRL and FABP3 are associated with mammary differentiation, it is 
feasible that IGF-II may also regulate FABP expression [Brisken et al., 2002].  IGF-II, 
a major mediator of proliferation in breast cancer, is expressed at high levels in cancer 
tissues due to a loss of parental imprinting.  Figure 2 shows the ligands and receptors 
of the IGF family.  IGF-II signals classically through the type 1 IGF receptor (IGF-
IR), resulting in growth promoting effects through activation of the PI3/Akt pathway and 
induction of cyclin D1 protein [Sachdev and Yee, 2006].  IGF-II also signals through 
other receptors, including insulin receptor A (IR-A) for metabolic effects, and IGF-IIR 
for IGF-II degradation [O’Dell and Day, 1998; Scott and Firth, 2004; Pandini et al., 
1999; Belfiore et al., 2009].  IGF-II has short and long forms, known as mIGF-II 
(mature IGF-II) and proIGF-II.  ProIGF-II and mIGF-II bind the IGF-1R with the same 
affinity, but proIGF-II is highly expressed in cancer, and has been shown to be more 
potent than mIGF-II in activating the PI3/Akt pathway [Singh et al., 2007; Singh et al., 
2008].  
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Figure 2. The IGF Family- Ligands and Receptors. IGF-II signals classically through 
the type 1 IGF receptor (IGF-IR) resulting in growth promoting effects, through the 
insulin receptor for metabolic effects, and through the type II IGF receptor for IGF-II 
degradation. 
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Role of PRL in Normal Breast Differentiation and in 
Carcinogenesis 
Another major proliferative mediator in breast cancer is PRL, which is produced 
by the pituitary gland and locally in breast tissue.  The Jak2-Stat5 pathway is the best 
studied.  When PRL binds to the long form of the PRL receptor (PRLR), there is a 
conformational change in and activation of preformed PRLR dimers.  This causes Jak2 
trans-phosphorylation, and eventual activation of Stat5 proteins by Jak2.  Stat5 
proteins become either homo- or heterodimers with other transcription factors, and then 
go to the nucleus, where they regulate gene transcription of beta-casein, cyclin D1, and 
other genes [Chen et al., 2009; Oakes et al., 2008; Clevenger et al., 2009].  PRL also 
activates MAP kinase, PKC delta, c-Src, and PI3-kinase, estrogen receptor alpha, and 
potassium channels in addition to the Jak2-Stat5 pathway [Chen et al., 2009; 
Gonzalez et al., 2009].  Though the PRLR long form is prototypical and has the entire 
spectrum of PRLR signaling capabilities, there are also short forms of the receptor 
which attenuate signaling [Swaminathan et al., 2008; Tan and Walker, 2009].  In the 
normal breast state, PRL is important in proliferation and differentiation of normal 
mammary epithelium and in stimulation of lactation (Figure 3).  Mean basal daily levels 
of PRL are 9-10 ng/ml in plasma.  Levels increase during pregnancy (15 to 25 times 
basal) and lactation (up to 30 times basal) and lead to full lobuloalveolar 
development of the breast [Tworoger and Hankinson, 2006; Bercovich and Goodman, 
2009]. As aforementioned, IGF-II mediates the differentiating effect of PRL in the 
breast through upregulation of cyclin D1 [Brisken et al., 2002].  Pregnancy and 
lactation, especially before the age of 24, has been shown to reduce pregnancy risk 
[Russo et al., 2005].  This may be due to the long-lasting reduction in PRL levels after 
13 
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Figure 3. Hormonal Regulation of Human Breast Development.  PRL acts on the breast 
tissue during pregnancy and lactation to induce terminal development of the milk glands. 
From http://www.elu.sgul.ac.uk/rehash/guest/scorm/228/package/content/index.htm  
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a first pregnancy that is consistently observed in both premenopausal and 
postmenopausal women [Tworoger and Hankinson, 2008].  In the breast cancer state, 
PRL fails to trigger differentiation and instead enhances breast epithelial survival by 
preventing the apoptosis of cancer cells, enhancing cell motility and invasive growth, 
and possibly supporting tumor vascularization [McHale et al., 2008; Howell et al., 
2008; Abdelmagid and Too, 2008; Plotnikov et al., 2009; Tworoger and Hankinson, 
2006].  Also, there is a decrease in the ratio of short forms to PRLR in tumor tissue and 
breast cancer cell lines, and thus, a loss of regulation [Swaminathan et  al., 2008].    
Since FABP3 is strongly expressed in breast tissues during the breast differentiation 
that is associated with pregnancy [Russo et al., 2005], it is possible that PRL may 
induce FABP3 expression.  
 
Significance of Studying IGF-II and PRL Regulation of FABP 
Expression 
The roles of IGF-II and PRL in breast cancer have been more than adequately 
investigated and demonstrated.  However, a possible relationship between PRL/IGF-II 
and FABPs 3 and 5 has not been studied.  Also, there have been no studies performed 
to date regarding the protective effect of significantly increased FABP3 levels, 
induced by PRL, in mammary epithelial cells.  Determining the effect of PRL and 
IGF-II on FABP3 levels in normal breast cell lines, established from AA and CA 
women, would possibly elucidate additional regulatory mechanisms for FABPs 3 and 
5, and would uncover therapeutic targets through which FABP3 could be upregulated.  
If we can demonstrate that FABP3 levels are regulated by IGF-II, then IGF-II levels 
could potentially be lowered in breast cancer patients so as to increase FABP3 levels and 
16 
thus cause tumor tissue to revert to more normal behavior.  If we can demonstrate that 
FABP3 levels are regulated by PRL, then PRL levels could potentially be increased 
in normal women, short-term, so as to induce protective FABP3 expression.  
Furthermore, examining the differential expression of FABP3 in response to IGF-II 
and PRL in AA and CA normal breast cell lines allows us to determine the potency 
of response between the ethnic groups, and is an exciting, groundbreaking study.  
Therefore, we proposed to complete the following:  assess expression of FABPs 3 
and 5 in paired normal/tumor breast tissues from AA and CA patients (from Human 
Cooperative Tissue Network) to determine if lower expression of FABP3/higher 
expression of FABP5 among AA women is associated with the disparity in breast cancer 
progression observed between AA and CA patients; assess expression of FABPs 3 and 5 
in normal and malignant breast epithelial cell lines established from CA and AA patients; 
and simulate breast differentiation by treating normal breast epithelial cell lines 
established from AA and CA patients with PRL to determine and compare effects on 
expression of IGF-II, FABP3, and FABP5.  Our studies have provided much needed 
information about the mechanisms involved in the protective effect lactation induces in 
the breast and will potentially offer new tools for preventive breast cancer treatment. 
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CHAPTER TWO 
PRL AND IGF-II REGULATION OF FATTY ACID-BINDING 
PROTEINS 3 AND 5 IN NORMAL BREAST EPITHELIAL CELLS 
 
Abstract 
Epidemiological studies have shown that lactation reduces the risk of breast 
cancer in young women.  Lactation’s protective effect is in part mediated by fatty-acid 
binding protein 3 (FABP3), which is associated with breast differentiation.  FABP5, a 
member of the same family, is also expressed in the breast and stimulates angiogenesis, 
essential for lactation.  The effects of prolactin (PRL), which stimulates breast 
differentiation and lactation, are mediated by IGF-II.  Thus, we propose that PRL 
treatment of normal epithelial breast cell lines increases IGF-II to promote differentiation, 
regulating FABP3 and FABP5.  We treated MCF10A and AG11132 normal breast 
epithelial cell lines with recombinant human PRL (0-200 ng/ml) for 24 hours.  Cell 
lysates were examined for protein and mRNA levels of IGF-II, FABP3, and FABP5.  In 
MCF10A cells, PRL treatment decreased FABP5 protein (p=0.044).  IGF-II mRNA 
levels significantly increased when cells were treated with 100 and 200 ng/ml PRL (2- 
and 2-fold, respectively).  In AG11132 cells, phosphorylated FABP3 protein increased, 
and FABP5 protein decreased, with increasing PRL concentration (p=0.037, 0.028, 
respectively).  IGF-II mRNA levels increased at 10 ng/ml PRL (34-fold). Though both 
cell lines responded to PRL with decreased FABP5 protein and increased IGF-II mRNA, 
only AG11132 displayed increased FABP3 protein. The dissimilar responsiveness of 
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these cell lines to PRL may suggest decreased protection against breast carcinogenesis in 
AA patients, and may help us to further understand this health disparity. 
 
Introduction 
Breast cancer is the number one cancer affecting women, taking first place in 
incidence, and second only to lung cancer in mortality.  Recently, health disparities 
between African-American (AA) and Caucasian-American (CA) breast cancer patients 
have come to the forefront.  AA and Hispanic patients present with more advanced stages 
of breast cancer and have lower survival rates than Whites [Li et al., 2003].  Additionally, 
the age specific breast cancer incidence rate for AA women under age 35 is more than 
twice the rate for white women of similar age, and the mortality rate is more than three 
times higher [Shavers et al., 2003].  
Socioeconomic factors play a predominant role in this disparity [Adams et al., 
2009].  In other cases, certain therapies, such as cancer-directed surgery for invasive 
breast cancer or radiation therapy, are recommended to AA women less frequently 
[Shavers et al., 2003].  Apart from socioeconomic factors, however, there is evidence of 
biological differences between AA and CA patients, as demonstrated in a recent study.  
Yancy and coworkers discovered that there were five metastasis-related genes (Atp1b1, 
CARD 10, KLF4, Spint2, Acly) whose expression significantly differed between AA and 
CA breast cancer cell lines [Yancy et al., 2007].  Further, we have reported that AA cell 
lines and breast tissues contain higher levels of IGF-II relative to CA cell lines and 
tissues [Kalla Singh et al., 2010].  Differences in levels of fatty acid binding proteins 
(FABPs) may be yet another biological factor, which may help to explain the differences 
in breast cancer presentation and survival between AA and CA patients.  
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Intracellular fatty acid-binding proteins (FABPs) are about 15 kDa in size, and are 
encoded by multiple genes. FABPs increase fatty acid solubility and transport them from 
the plasma membrane to various sites within the cell, including to the nucleus, to promote 
transcription of genes by binding peroxisome proliferator-activated receptors (PPARs) 
[Hertzel and Bernlohr, 2000; Zimmerman and Veerkamp, 2002; Glatz and van der Vusse, 
1996].  Several FABPs are expressed in mammary tissue, including FABP3 and FABP5. 
FABP3 has been shown to be highly expressed in differentiated mammary tissue, while 
FABP5 has been shown to be upregulated in pathologic states in various tissues 
throughout the body [De León et al., 1996].  
 FABP3, also known as mammary derived growth inhibitor (MDGI), has been 
shown to regulate growth of normal mouse mammary epithelial cells, promote normal 
mammary gland differentiation, and stimulate milk protein synthesis [Yang et al., 1994; 
Specht et al., 1996; Borchers et al., 1997].  FABP3 binds to the nuclear receptor PPARα, 
and inhibits production of VEGF, which promotes angiogenesis and metastasis 
[Schroeder et al., 2008].  Additionally, stimulation of PPARα and PPARγ causes 
FABP3 upregulation [Motojima, 2000; Lindegaard and Nielsen, 2008; Keen et al., 2004].  
In breast cancer tissues, levels of FABP3 are downregulated, and the gene may even be 
silenced in many human breast cancers [Hertzel and Bernlohr, 2000; Huynh et al., 1996].  
FABP3 has a well-demonstrated tumor-suppressing role: when the gene is introduced 
into MCF-7 breast cancer cells, they revert to more normal behavior [Huynh et al., 1996; 
Huynh and Beamer, 1998].  Pregnancy and lactation has been shown to be protective 
against breast cancer development in rats and in humans [Russo et al., 1982; Sinha et al., 
1988; Russo et al., 2005], and the induction of FABP3 expression in the breast may help 
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to explain this. Pregnancy and lactation alter the genetic profile of the mammary cells so 
as to render them refractory to carcinogenesis, and FABP3 is the only FABP that is a part 
of this protective genetic profile [Russo et al., 2005].  Studies indicate that AA women 
have lower lactation rates compared to all other ethnic groups, and therefore the induction 
of FABP3 expression may not be as significant in this group as a whole, relative to CA 
women [Bentley et al., 2003].  FABP3 levels may be regulated by PRL and IGF-II, as 
PRL is the major hormonal influence during pregnancy and lactation, and IGF-II 
mediates PRL’s effects [Oakes et al., 2008; Brisken et al., 2002].  During pregnancy, 
PRL levels in the plasma increase to 15 to 25 times the basal level; during lactation, 
levels increase up to 30 times the basal level. This increased expression leads to full 
lobulo-alveolar development of the breast [Tworoger and Hankinson, 2006; Bercovich 
and Goodman, 2009].  PRL binds to its receptor (PRLR) to effect these changes.  There 
are several forms of the PRLR, including the long form (85-95 kDa), the delta S1 form 
and S2 forms (both 70 kDa), the intermediate form (50 kDa), the short form 1b (SF1b; 29 
kDa), and the short form 1a (SF1a; 39 kDa). The delta S1 form has the full signaling 
capabilities of the long form but requires more ligand, the delta S2 form prevents 
constitutive activation of the PRLR, and the intermediate form enhances cell survival but 
has limited proliferative effects. The short forms are dominant negatives to the long form, 
with SF1b being stronger than SF1a [Clevenger et al., 2009; Swaminathan et al., 2008; 
Tan and Walker, 2010; Tan et al., 2008]. 
FABP5 is upregulated in a number of states with disturbed lipid profiles. The 
literature shows that FABPs have a compensatory relationship within tissues 
[Zimmerman and Veerkamp, 2002; Shaughnessy et al., 2000].  For example, in FABP5-
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gene knockout mice, FABP3 was elevated in the liver [Owada et al., 2002] and in FABP4 
(adipocyte type)- knockout mice, FABP5 mRNA was upregulated in adipocytes 20- to 
40-fold [Hertzel and Bernlohr, 2000].  The fabp5 gene is an inducer of metastasis, and its 
mRNA levels are 6.5-fold higher in malignant breast cell lines compared to HUMA 121 
benign lines [Jing et al., 2000].  It is thought that FABP5 transports nucleic acids to the 
nuclear receptor PPAR β/δ, where they bind and cause upregulation of vascular 
endothelial growth factor (VEGF) [Kannan-Thulasiraman et al., 2010; Schug et al., 
2007].  VEGF is overexpressed in a significant percentage of breast tumors, and this 
expression has been associated with a worse prognosis in patients with invasive breast 
disease [Bajo et al., 2004; Heffelfinger et al., 1999; Gieseler et al., 2007].  Though 
FABP5 has a metastasis-promoting role in cancer cells, it has a beneficial role in breast 
differentiation.  Bovine studies have shown that both FABP3 and FABP5 mRNA 
increase upon pregnancy and lactation (which corresponds with breast differentiation); 
however, FABP3 increases to a greater extent than FABP5, and stays elevated for a 
longer period of time [Bionaz and Loor, 2008].  Thus, PRL, the main hormone that 
induces breast differentiation during pregnancy and lactation, may also regulate FABP5 
levels, though this has not yet been shown in the literature. Due to FABPs’ compensatory 
relationship, it is also possible that a large increase in FABP3 could be associated with a 
FABP5 decrease.   
To determine if response to PRL was a factor in the differential FABP3 levels 
expressed in AA and CA benign tissues in ages below 50, we treated AA and CA benign 
cell lines with recombinant human PRL and measured the change in FABP3 protein and 
mRNA. We also measured FABP5 levels to determine if there would be a compensatory 
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relationship between FABP5 and FABP3 levels in these cells, and if decreased FABP5 
would be associated with differentiation in these cells. Since IGF-II is the mediator of 
PRL’s effects, we measured IGF-II levels, and thus assessed for IGF-II regulation of 
FABP changes. Lastly, we measured PRL receptor (PRLR) levels to account for potential 
differences in forms of PRLR expressed, and in the responses of the cell lines to PRL. 
 
Materials and Methods 
Cell Culture 
MCF10A normal breast epithelial cell line was obtained from the American Type 
Culture Collection (Manassas, VA).  This non-tumorigenic, estrogen and progesterone 
receptor negative line was established from a 36 year old Caucasian-American patient 
with fibrocystic disease.  MCF10A cells were maintained in a 5% CO2 incubator at 37 
oC, using Dulbecco’s modified eagle’s medium (DMEM)/F12 50:50 media (Cellgro) 
supplemented with 5 ml of penicillin/streptomycin (10,000 I.U./ml penicillin, 10,000 
µg/ml streptomycin sulfate; Cellgro), 2 mM L-glutamine (Cellgro), 10 µg/ml insulin 
(Sigma, St. Louis, MO), 0.5 µg/ml hydrocortisone (Sigma), murine epidermal growth 
factor (EGF) 20 ng/ml (Sigma), cholera toxin 100 ng/ml (Sigma), and 5% bovine serum 
albumin (HyClone). AG11132 normal breast epithelial cell line was obtained from the 
Coriell Institute (Camden, NJ).  This non-tumorigenic, estrogen receptor poor line was 
established from a 16 year old African-American patient who underwent reduction 
mammoplasty.  AG11132 cells were maintained in a 5% CO2 incubator at 37 oC, using 
Clonetics Mammary Epithelium Basal Medium (MEBM) media (Lonza) supplemented 
with 70 µg/ml bovine pituitary extract, 0.5 µg/ml hydrocortisone, 5 µg/ml insulin, and 5 
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ng/ml human epidermal growth factor (EGF) from the MEGM BulletKit; 10 µM 
isoproterenol (Sigma); and 5 µg/ml transferrin (Sigma).  Recombinant human PRL was 
purchased from R&D Systems (Minneapolis, MN).  MCF10A and AG11132 cells were 
seeded at a density of 2 x 105 cells/well in six-well plates; one plate per cell line to allow 
for triplicate assays.  Cells were incubated at 37 oC in a 5% CO2 incubator.  At 80% 
confluence, media on both cell lines was changed to serum-free DMEM supplemented 
with 5 ml penicillin/streptomycin, and cells were incubated for 6 hours prior to treatment.   
PRL treatment was then performed for 24 hours in fresh serum-free DMEM 
supplemented with 5 ml penicillin/streptomycin; cells were incubated for the duration of 
treatment.  Cell lysates for protein analysis were prepared using radioimmuniprecipitation 
assay (RIPA) buffer (Santa Cruz Biotechnology, Santa Cruz, CA), according to 
manufacturer protocol (http://www.cellsignal.com/products/9806.html) and stored at -20 
oC until assayed.  Cell lysates for RNA analysis were prepared using TRI Reagent 
(Molecular Research Center, Cincinnati, OH) according to manufacturer protocol 
(http://www.mrcgene.com/tri.htm) and stored at -20 oC until assayed. 
 
PRL Treatment 
MCF10A and AG11132 cells were seeded at a density of 2 x 105 cells/well in six-
well plates.  Recombinant human PRL (R&D Systems, Minneapolis, MN) was diluted in 
vehicle of 1X PBS w/0.1% BSA.  Various concentrations of PRL—0 (vehicle control), 
10, 50, 100, and 200 ng/ml were added to the cells followed by 24 h incubation at 37 oC 
in a 5% CO2 incubator.  Concentrations were chosen to mimic physiological basal PRL 
concentration (9-10 ng/ml), as well as concentrations during pregnancy and lactation 
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(150-300 ng/ml).  Treatments were performed in triplicate.  Cell lysates for protein 
analysis were prepared using RIPA buffer according to manufacturer protocol and stored 
at -20 oC until assayed.  Cell lysates for RNA analysis were prepared using TRI Reagent 
according to manufacturer protocol and stored at -20 oC until assayed. 
 
Western Blot Analysis 
Total protein (30 µg) of cell lysates were collected after 24 h of PRL treatment 
and used to load polyacrylamide sodium dodecyl sulfate (SDS) gradient gels (4-12%), 
transferred to a polyvinylidene difluoride (PVDF) membrane (Invitrogen, Carlsbad, CA) 
using a X-Cell SureLock ® electrophoretic transfer module (Invitrogen).  Protein 
concentration was measured using the Coomassie Plus Protein Assay Reagent ™ (Pierce 
Biotechnology, Rockford, IL).  PVDF membranes were then blocked with 5% non-fat 
milk or 5% bovine serum albumin (Sigma) in PBS/0.05% Tween for 1 h.  Membranes 
were then incubated with IGF-II monoclonal antibody (Amano, Mitsubishi, Troy, VA), 
FABP3 monoclonal antibody (Abcam, Cambridge, UK), FABP5 polyclonal antibody 
(Abcam, Cambridge, UK), or PRL receptor monoclonal antibody (Invitrogen), followed 
by overnight incubation at 4 oC.  The blots were also probed with ß-actin antibody 
(Sigma) as a protein loading control.  After 3 x 10 min washes in PBS/0.05% Tween, the 
corresponding secondary antibodies (1:1000, GE Healthcare, Piscataway, NJ) were added 
to the membranes (1 h at room temperature), followed by 3 x 10 min washes and 
incubation with horseradish peroxidase (HRP) complexes (1:2000, GE Healthcare).  
Protein visualization was achieved by using enhanced chemiluminescence (ECL) and 
autoradiography with Blue Lite Autorad film (GeneMate from BioExpress, Kaysville, 
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UT).  The signals on the X-ray films were quantified using QuantityOne 1-D Analysis 
Software v. 4.5.0 (BioRad, Hercules, CA). 
 
Real-Time PCR 
Two-step SYBR real-time-PCR (RT-PCR) was performed to assess gene 
expression in PRL- treated cells at 24 h, using the primers FABP3-forward (5’-CAC TAT 
GGT GGA CGC TTT CC-3’), and FABP3-reverse (5’-GTG GTA GGC TTG GTC ATG 
CT-3’); FABP5-forward (5’-ACA GAT GGT GCA TTG GTT CA-3’), and FAB5-
reverse (5’-GAT CCG AGT ACA GGT GAC ATT G-3’); IGF-II-forward (5’-GAC CGC 
GGC TTC TAC TTC AG-3’), and IGF-II reverse (5’-AAG AAC TTG CCC ACG GGG 
TAT-3’).  Primers for FABP3 utilized NCBI RefSeq NM_004102.3 and resulted in a 126 
bp-length product; primers for FABP5 utilized NCBI RefSeq NM_001444.2 and resulted 
in a 123 bp-length product.  Primer 3 software version 0.4.0 (http://frodo.wi.mit.edu/) 
was used to generate primers, and NCBI PrimerBlast was used to test specificity.  The 
iScript cDNA synthesis kit (Bio-Rad) and GeneAmp PCR System 9700 (PE Applied 
Biosystems, Foster City, CA) were used to synthesize cDNA; 400 ng of RNA was used 
per synthesis reaction.  RT-PCR was performed using the iQ5 (Bio-Rad) and the iQ 
SYBR Green Supermix (Bio-Rad).  Reactions were performed in a mixture consisting of 
a 25 µl volume solution containing SYBR Green supermix PCR buffer (Bio-Rad; 2x 
reaction buffer with dNTPs, iTaq DNA polymerase, 6 mm MgCl2, SYBR Green I, 
fluorescein, and stabilizers), 1 µl of synthesized cDNA, 400 nM of each primer, and 
sterile water.  Forty cycles of denaturation (95 oC, 15 s), annealing (60 oC, 30 s), and 
elongation (72 oC, 10 s) were performed.  Fluorescence was detected at the end of every 
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72 oC extension phase.  Melting curve analysis was done to exclude contamination by 
non-specific PCR products. 
 
Cell Viability Assay 
Cell viability was measured by the colorimetric water soluble tetrazolium salt-1 
(WST-1) assay (Roche, Mannheim, Germany), according to manufacturer protocol.  Cells 
(5000 cells/well) were seeded in 96-well plates and grown in culture media as described 
above.  Cell viability was assessed at 24 h post-treatment with PRL by reading the 
absorbance at 450 nm. 
 
Statistical Analysis 
Values are expressed as the mean ± SEM of three replicate experiments.  For 
protein values, statistical differences were determined by independent samples t-test (to 
compare 2 means) or one-way ANOVA (to compare greater than 2 means), SPSS 19.0 
software (IBM, Armonk, New York).  A level of p < 0.05 was considered significant.  
For mRNA values, fold change was calculated, and statistical significance was set at a 
fold change of 2 or greater. 
 
Results 
Untreated Cells 
Protein Levels 
As shown in Figure 4, FABP3 and 5 protein levels in untreated AG11132 and 
MCF10A cells were significantly higher in the MCF10A cell line relative to the 
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AG11132 line (p < 0.001 for both FABPs).  Figure 5 demonstrates that protein levels of 
PRL and of IGF-II were significantly higher in MCF10A cells (p = 0.003, 0.002, 
respectively) relative to AG11132 cells.  FABP3 mRNA was detectable in AG11132 
cells but not in MCF10A cells.  FABP5 was 6052-fold higher than FABP3 in AG11132 
cells.  
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Figure 4.  Western Blot of FABPs 3 and 5 in Nontransformed Breast Epithelial Cells.  A. 
Levels of FABPs 3 and 5 in AG11132 and MCF10A cells.  FABP3 and FABP5 were 
significantly increased in MCF10A cells relative to AG11132 cells (p < 0.001 for both 
FABPs).  IDV- integrated density values.  B. Representative Western blots of FABPs 3 
and 5 in AG11132 and MCF10A cells.   
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Figure 5.  Western Blot of PRL and IGF-II in Nontransformed Breast Epithelial Cells.  A. 
Levels of PRL and IGF-II in AG11132 and MCF10A cells.  PRL and IGF-II were 
significantly increased in MCF10A cells relative to AG11132 cells (p = 0.003 for PRL, p 
= 0.002 for IGF-II).  IDV- integrated density values.  B. Representative Western blots of 
PRL and IGF-II in AG11132 and MCF10A cells. 
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Messenger RNA Levels 
As shown in Figure 6, FABP5 mRNA was 2-fold higher in MCF10A cells relative 
to AG11132 cells.  Conversely, PRL and IGF-II mRNA were higher in AG11132 cells 
relative to MCF10A cells (2-fold and 43-fold, respectively).  
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Figure 6.  Messenger RNA Levels of FABP5, IGF-II, and PRL in Nontransformed Breast 
Epithelial Cells.  FABP5 mRNA was 2-fold higher in MCF10A cells relative to 
AG11132 cells.  PRL and IGF-II mRNA were higher in AG11132 cells relative to 
MCF10A cells (2-fold and 43-fold, respectively).  FABP3 mRNA was not detected in 
MCF10A, thus a comparison could not have been made. 
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PRL-Treated Cells 
Protein Response 
Figure 7 shows the protein response of AG11132 cells to PRL treatment.  FABP3 
(18 kDa form) at 200 ng/ml was significantly increased relative to control (p=0.037).  
FABP5 was significantly decreased at 200 ng/ml relative to level at 10 ng/ml (p=0.028). 
No significant change was noted in IGF-II protein.  Figure 8 shows the protein response 
of MCF10A cells to PRL treatment.  FABP3 (18 kDa form) was significantly decreased 
at 200 ng/ml relative to levels at 0, 10, 50, and 100 ng/ml (p=0.002, 0.004, <0.001, 0.001, 
respectively).  FABP5 at 200 ng/ml was significantly decreased relative to level at 50 
ng/ml (p=0.044).  No significant change was noted in IGF-II protein.   
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Figure 7.  Western Blot of IGF-II, FABP3, and FABP5 in PRL-Treated AG11132 Cells.  
A. Levels of IGF-II, FABP3, and FABP5 protein at various PRL treatment 
concentrations.  FABP3 (18 kDa form) was significantly increased at 200 ng/ml 
(p=0.037) relative to control.  FABP5 was significantly decreased at 200 ng/ml relative to 
level at 10 ng/ml (p=0.028).  IDV- integrated density values.  B. Representative Western 
blots of IGF-II, FABP3, and FABP5 in PRL-treated AG11132 cells.  
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Figure 8.  Western Blot of IGF-II, FABP3, and FABP5 in PRL-Treated MCF10A Cells.  
A. Levels of IGF-II, FABP3, and FABP5 protein at various PRL treatment 
concentrations.  FABP3 (18 kDa form) was significantly decreased at 200 ng/ml relative 
to levels at 0, 10, 50, and 100 ng/ml (p = 0.002, 0.004, <0.001, 0.001, respectively).  
FABP5 was significantly decreased at 200 ng/ml relative to level at 50 ng/ml (p=0.044).  
IDV- integrated density values.  B. Representative Western blots of IGF-II, FABP3, and 
FABP5 in PRL-treated MCF10A cells. 
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Messenger RNA Response 
Figure 9 shows that for AG11132 cells, levels of IGF-II mRNA were significantly 
increased at 10 ng/ml and 50 ng/ml (fold change 34 and 2, respectively).  IGF-II mRNA 
levels decreased with further increase in PRL treatment concentration.  No significant 
changes were seen in FABP3 or FABP5 mRNA levels.  The mRNA response of 
MCF10A cells is shown in Figure 10.  IGF-II levels were significantly increased at 100 
and 200 ng/ml (fold change 2 and 2, respectively).  No significant changes were seen in 
FABP3 or FABP5 mRNA levels.   
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Figure 9.  Messenger RNA Levels of IGF-II, FABP3, and FABP5 in PRL-Treated 
AG11132 Cells.  A. Levels of IGF-II mRNA at various PRL treatment concentrations.  
IGF-II mRNA levels were significantly higher at 10 ng/ml (34-fold) and 50 ng/ml (2-
fold) of PRL treatment, relative to control.  B. Levels of FABP3 and FABP5 mRNA at 
various PRL treatment concentrations.  No significant differences were seen in FABP 
mRNA levels with treatment. Note difference in scale between graphs of IGF-II and 
FABP mRNA levels. 
 
 
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Messenger RNA Levels of IGF-II, FABP3, and FABP5 in PRL-Treated 
MCF10A Cells.  A. Levels of IGF-II mRNA at various PRL treatment concentrations.  
IGF-II levels were significantly increased at 100 (2-fold) and 200 ng/ml (2-fold) of PRL 
treatment.  B. Levels of FABP3 and FABP5 mRNA at various PRL treatment 
concentrations.  No significant differences were seen in FABP mRNA levels with 
treatment. 
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Discussion 
The higher levels of both FABP3 and FABP5 protein in untreated MCF10A cells, 
relative to untreated AG11132 cells, may suggest a more differentiated cell status.  
Bovine studies have shown that both FABP3 and FABP5 mRNA increase upon 
pregnancy and lactation (which corresponds with breast differentiation); however, 
FABP3 increases to a greater extent than FABP5, and stays elevated for a longer period 
of time [Bionaz and Loor, 2008].  FABP5 mRNA was also higher in MCF10A cells than 
AG11132 cells.  However, FABP3 mRNA was undetectable in MCF10A cells, and 
detected at low levels in AG11132 cells.  This may indicate that FABP5 has a greater role 
in normal cell functioning which includes intracellular fatty acid transport, while FABP3 
may have a more differentiation-specific role (i.e., FABP3 mRNA levels only increase 
when the cells receive a differentiation stimulus).  FABP5-mediated upregulation of 
VEGF may lead to appropriate proliferation in normal cells.   
Untreated MCF10A cells also had higher levels of PRL and IGF-II protein than 
untreated AG11132 cells.  Levels of PRL and IGF-II mRNA were significantly higher in 
AG11132 cells, particularly IGF-II levels, which were over 40-fold higher.  This finding 
is consistent with previous results from our laboratory, which demonstrated higher IGF-II 
mRNA levels in AA normal breast tissue relative to CA normal tissue, with the 
difference most pronounced in women below 45 years of age [Kalla Singh et al., 2010].  
The higher IGF-II levels in AG11132 normal cells and in AA normal breast tissue may 
indicate a greater potential for carcinogenic transformation.  IGF-II is expressed at high 
levels in cancer tissues due to a loss of parental imprinting, and is a major mediator of 
proliferation in breast cancer [Sachdev and Yee, 2006].     
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AG11132 cells responded to PRL treatment with increased FABP3 protein (18 
kDa form) and decreased FABP5 protein at 200 ng/ml treatment, both changes associated 
with protection against carcinogenesis [Schonfeld and Wojtczak, 2008; Ishii, 2007; 
Rohan et al., 2010].  The increase in FABP3 was likely due to the lower levels of FABP3 
in untreated AG11132 cells, which may represent a lower baseline level of protection 
against carcinogenesis in these cells.  The dominant PRLR form in the AG11132 cell line 
was the 70 kDa form, representing delta S1 and/or S2, and the long form of the PRLR 
was not expressed (data not shown).  With regard to mRNA levels, IGF-II mRNA 
increased several-fold with 10 ng/ml PRL, increased modestly with 50 ng/ml PRL, and 
then was further decreased at higher PRL concentrations.  This may have been due to 
negative feedback, as IGF-II mRNA was several-fold higher in untreated AG11132 cells 
relative to MCF10A cells.  This may also indicate that PRL’s effects were mediated 
through IGF-II at lower treatment concentrations, but not at higher concentrations.  
Though IGF-II has been reported to mediate PRL’s differentiation effects through 
upregulation of cyclin D1, there is some evidence that IGF-II may not be required for 
these effects in all cases [Brisken et al., 2002; Hovey et al., 2003].  For example, Carver 
and Schuler demonstrated that in the MCF-7 breast cancer cell line, PRL was able to 
induce cyclin D1 expression prior to upregulation of IGF-II transcript levels, suggesting 
that though PRL caused IGF-II increase, this was not required for signaling [Carver and 
Schuler, 2008]. 
Since MCF10A cells had higher FABP3, PRL, and IGF-II protein levels prior to 
PRL treatment, relative to AG11132 cells, it followed that FABP3 protein levels were 
maintained with PRL treatment, and then decreased at the highest PRL concentration.  
47 
The dominant PRLR form in this cell line was the 70 kDa form; however, MCF10A cells 
also expressed the 85-90 kDa long form of PRLR, though not as strongly (data not 
shown).  Thus the decrease in FABP3 protein may represent negative feedback due to 
PRLR overstimulation at high PRL concentrations.  FABP5 protein levels significantly 
decreased with 200 ng/ml PRL treatment, likely reflecting decreased carcinogenic 
potential of the cells.  With regard to mRNA levels, significant increases were seen in 
IGF-II mRNA at 100 ng/ml and 200 ng/ml, pointing to IGF-II signaling in maintenance 
of FABP3 levels.  These increases were modest relative to increases seen in the AG11132 
cell line; this may have been due to higher initial levels of IGF-II protein in MCF10A 
cells.  
In summary, the AG11132 cell line displayed several differences compared to the 
MCF10A cell line, which may help us understand the increased mortality in AA breast 
cancer patients.  The differing growth conditions of the cell lines is a potential drawback 
of this study; however, serum-free media was placed on both cell lines for 6 hours prior 
to and also during the treatment, to enable comparison of results.  AG11132 cells 
displayed decreased FABP3 protein at baseline, in comparison to MCF10A cells, likely 
indicative of lower protection against carcinogenesis.  FABP3 protein increased in 
AG11132 cells with increasing PRL treatment concentration, but decreased in MCF10A 
cells, likely due to higher initial FABP3 protein levels and expression of the PRLR long 
form in the latter.  Interestingly, the significant FABP3 changes in both cell lines are seen 
in the 18 kDa form, which is most likely tyrosine-phosphorylated.  FABP3 from rat heart 
has been shown to be phosphorylated on Tyr19 in response to insulin stimulation, and 
according to PhosphoSite Plus, an NIH-supported site which predicts post-translational 
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protein modifications, human FABP3 is tyrosine-phosphorylated on Tyr-20 [Nielsen and 
Spener, 1993; Cell Signaling, 2012].  The role of phosphorylation in FABP3 function is 
as yet unknown, but has been proposed to be related to signal transduction and/or 
regulation [Huynh et al., 1996; Nielsen and Spener, 1993].  Decreased FABP5 protein 
was observed with treatment in both cell lines, which is protective against future 
carcinogenesis.  PRL treatment of AG11132 cells at 10 ng/ml was associated with a 
several-fold increase in IGF-II mRNA; however, levels decreased with subsequent 
increases in PRL concentration, indicating that PRL signaling in AG11132 cells may not 
involve IGF-II at higher treatment concentrations.  PRL treatment of MCF10A cells did 
result in increased IGF-II mRNA at highest PRL concentrations, suggesting that PRL is 
mediating its differentiation changes through IGF-II in this cell line.  
Understanding possible molecular mechanisms underlying the breast cancer 
health disparity is crucial to its resolution, along with addressing socioeconomic and 
access-to-care concerns.  In order to apply these findings to the larger population, PRL 
treatment would need to be done in other CA and AA normal cell lines in order to 
determine if these findings are unique to the particular cell lines studied, or if they 
represent common patterns of PRL signaling and FABP3 expression in cell lines derived 
from CA and AA patients.  The studies described here provide preliminary insights into 
possible mechanisms undergirding the survival health disparity observed among AA 
women affected with breast cancer.  
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CHAPTER THREE 
DIFFERENTIAL EXPRESSION OF FATTY ACID-BINDING 
PROTEINS 3 AND 5 IN CAUCASIAN-AMERICAN AND AFRICAN-
AMERICAN BREAST TISSUES 
 
Abstract 
While Caucasian-American (CA) women have a higher overall breast cancer 
incidence relative to African-American (AA) women, AA women have a higher mortality 
rate.  Fatty acid-binding protein (FABP) 3 is a protective tumor suppressor that is 
downregulated in breast cancer tissues.  FABP5 is associated with metastasis, and is 
upregulated in breast cancer tissues.  We hypothesized that AA women would express 
lower levels of FABP3 and higher levels of FABP5, as shown by analysis of 94 paired 
(normal/tumor) breast tissues.  Contrary to expectations, FABP3 protein in AA malignant 
(AAM) samples was higher than in CAM samples in ages below 50.  FABP5 protein was 
higher in AAM samples relative to CAM samples when data were not split by age.  In 
ages 50 and older, FABP3 mRNA was significantly higher in CAM, while FABP5 
mRNA was significantly higher in AAM.  These findings demonstrate that differential 
FABP expression may be implicated in the breast cancer health disparity. 
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Introduction 
Breast cancer is a significant cause of female mortality, second only to lung 
cancer.  In recent years, significant emphasis has been put on cancer health disparities 
among ethnic groups.  African-American (AA) women are less likely than Caucasian-
American (CA) women to develop breast cancer.  However, AA women are more likely 
to present with advanced disease, and have a higher mortality rate from breast cancer, as 
compared to CA women [Li et al., 2003].  Several studies have indicated that 
socioeconomic factors are clearly related to the disparities problem [Adams et al., 2009; 
Shavers et al., 2003].  In recent years, investigators have begun to examine biological 
factors that may be implicated as well [Kalla Singh et al., 2010; Yang et al., 1994].  One 
such factor may be differential expression of fatty acid binding proteins (FABPs). 
FABPs, approximately 15 kDa in size, are proteins which shuttle long chain fatty 
acids throughout cells, similar to albumin’s role in the circulation [Glatz and van der 
Vusse, 1996].  FABPs move fatty acids to sites of oxidation and esterification, as well as 
into the nucleus, where the fatty acids signal through peroxisome proliferator-activated 
receptors (PPARs) to affect gene transcription [Coe and Bernlohr, 1998; Hertzel and 
Bernlohr, 2000; Zimmerman and Veerkamp, 2002].  FABPs are expressed in various 
tissues of the body, including the breast, and have been shown to have a compensatory 
relationship.  For example, in FABP5-gene knockout mice, FABP3 was elevated in the 
liver [Owada et al., 2002] and in FABP4 (adipocyte type)- knockout mice, FABP5 
mRNA was upregulated in adipocytes 20- to 40-fold [Hertzel and Bernlohr, 2000].  
Breast tissue/cell lines have been shown to express FABP1, FABP3, FABP4, FABP5, 
and FABP7 [Hammamieh et al., 2005; Huynh et al., 1996; Liu et al., 2011]. 
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FABP3 expression in breast tissue is of particular interest since it is has been 
shown to regulate growth of normal human and some malignant mouse and human 
mammary epithelial cell lines [Borchers et al., 1997; Huynh and Beamer, 1998; Lehmann 
et al., 1989].  Previous literature reports downregulation or silencing of FABP3 levels in 
breast cancer tissues [Hertzel and Bernlohr, 2000; Huynh and Beamer, 1998].  FABP3 
has been shown to bind to the nuclear receptor PPARα, and thus inhibit production of 
VEGF, which promotes angiogenesis and metastasis [Schroeder et al., 2008].  
Additionally, stimulation of PPARα and PPARγ causes FABP3 upregulation 
[Motojima, 2000; Lindegaard and Nielsen, 2008; Keen et al., 2004].  Pregnancy and 
lactation protects against future breast cancer development in rats and in humans, and the 
induction of FABP3 expression in the breast may help to explain this [Russo, Moral et 
al., 2005; Russo et al., 1982; Sinha et al., 1988].  During pregnancy and lactation, 
mammary cells attain maximal development, and their genetic profile is altered to render 
them refractory to carcinogenesis, and FABP3 is the only FABP that is upregulated in 
this new genetic profile [Borchers et al., 1997; Russo, Moral et al., 2005; Specht et al., 
1996; Yang et al., 1994].  AA women have lower lactation rates compared to all other 
ethnic groups [Bentley et al., 2003], and therefore FABP3 levels may not be induced as 
highly as in CA women, leading to decreased protection. 
Another FABP that is very pertinent to breast carcinogenesis is FABP5.  The 
fabp5 gene has been linked to breast cancer metastasis, and mRNA levels were found to 
be 6.5-fold higher in malignant breast cell lines relative to HUMA 121 benign lines [Jing 
et al., 2000].  FABP5 expression has also been determined to be a negative prognostic 
factor for breast cancer patients, particularly those with triple-negative breast cancer [Liu 
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et al., 2011; Münz et al., 2005].  FABP5 is thought to transport nucleic acids to the 
nuclear receptor PPAR β/δ, where they bind and cause upregulation of vascular 
endothelial growth factor (VEGF) [Kannan-Thulasiraman et al., 2010; Schug et al., 
2007].  VEGF is overexpressed in a significant percentage of breast tumors, and this 
expression has been associated with a worse prognosis in patients with invasive breast 
disease [Bajo et al., 2004; Gieseler 2007; Heffelfinger et al., 1999].  Though the literature 
on the role of FABP5 in breast is heavily focused on the association of FABP5 with 
tumor aggressiveness and metastasis, FABP5 has also been shown to have a beneficial 
role in breast differentiation.  Bovine studies have shown that both FABP3 and FABP5 
mRNA increase upon pregnancy and lactation; however, FABP3 increases to a greater 
extent than FABP5, and stays elevated for a longer period of time [Bionaz and Loor, 
2008].  Given the decreased lactation rate in AA women, FABP3 may be lower in AA 
normal women relative to CA normal counterparts.  Given that AA women tend to have 
more aggressive cancer at time of diagnosis, the FABP5 levels may be higher in AA 
breast cancer patients relative to CA counterparts.  Furthermore, FABPs have a 
compensatory relationship in the tissues of the body, and have been shown to increase to 
compensate for deficits in another type of FABP [Hertzel and Bernlohr, 2000; Owada et 
al., 2002; Shaughnessy et al., 2000; Zimmerman and Veerkamp, 2002].  Therefore, this 
may be an alternate rationale for increased FABP5 levels in AA breast cancer patients 
relative to CA counterparts, as FABP3 levels may likely be decreased in the former. 
To determine if expression of FABP3 and FABP5 differed between AA and CA 
breast cancer patients, we obtained frozen normal and malignant breast tissues, and 
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analyzed protein levels by immunoprecipitation, and mRNA levels by RT-PCR.  
Findings were compared by age, race, and by normal/malignant status.   
 
Materials and Methods 
Sample Preparation 
Frozen, paired samples, AA and CA, were obtained from the Cooperative Human 
Tissue Network.  Portions of each sample (0.2 mg) were cut on dry ice under sterile 
conditions.  Tissues (0.1 mg) were homogenized in Tri Reagent (Molecular Research 
Center, OH) for mRNA extraction, according to standard Tri Reagent protocol 
(http://www.mrcgene.com/tri.htm).  Tissues (0.1 g) were also homogenized in RIPA 
Buffer (Cell Signaling Technology, Beverly, MA) for protein extraction, according to 
standard RIPA Buffer protocol (http://www.cellsignal.com/products/9806.html). 
 
Western Blot Analysis 
RIPA buffer cell lysates containing 30 µg of protein were loaded onto 
polyacrylamide sodium dodecyl sulfate (SDS) gradient gels (4-12%), transferred to a 
polyvinylidene difluoride (PVDF) membrane (Invitrogen, Carlsbad, CA) using a X-Cell 
SureLock ® electrophoretic transfer module (Invitrogen).  Protein concentration was 
measured using the Coomassie Plus Protein Assay Reagent ™ (Pierce Biotechnology, 
Rockford, IL).  PVDF membranes were then blocked with 5% non-fat milk or 5% bovine 
serum albumin (Sigma) in PBS/0.05% Tween for 1 h.  Membranes were then incubated 
with FABP3 mouse monoclonal antibody (Abcam, Cambridge, UK) or FABP5 rabbit 
polyclonal antibody (Abcam), followed by overnight incubation at 4 oC.  The blots were 
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also probed with cytokeratin 18 antibody (Sigma) as a protein loading control.  After 3 x 
10 min washes in PBS/0.05% Tween, the corresponding secondary antibodies (1:1000, 
GE Healthcare, Piscataway, NJ for FABP5; 1:1000, Vector, Burlingame, CA for FABP3) 
were added to the membranes (1 h at room temperature), followed by 3 x 10 min washes 
and incubation with horseradish peroxidase (HRP) complexes (1:2000, GE Healthcare).  
Protein visualization was achieved by using enhanced chemiluminescence (ECL) and 
autoradiography with Blue Lite Autorad film (GeneMate from BioExpress, Kaysville, 
UT).  The signals on the X-ray films were quantified using QuantityOne 1-D Analysis 
Software v. 4.5.0 (BioRad, Hercules, CA). 
 
Real-Time PCR 
Two-step SYBR real-time-PCR (RT-PCR) was performed to assess gene 
expression in PRL treated cells at 24 h, using the primers FABP3-forward (5’-CAC TAT 
GGT GGA CGC TTT CC-3’), and FABP3-reverse (5’-GTG GTA GGC TTG GTC ATG 
CT-3’); FABP5-forward (5’-ACA GAT GGT GCA TTG GTT CA-3’), and FAB5-
reverse (5’-GAT CCG AGT ACA GGT GAC ATT G-3’).  Primers for FABP3 utilized 
NCBI RefSeq NM_004102.3 and resulted in a 126 bp-length product; primers for FABP5 
utilized NCBI RefSeq NM_001444.2 and resulted in a 123 bp-length product.  Primer 3 
software version 0.4.0 (http://frodo.wi.mit.edu/) was used to generate primers, and NCBI 
PrimerBlast was used to test specificity.  The iScript cDNA synthesis kit (Bio-Rad) and 
GeneAmp PCR System 9700 (PE Applied Biosystems, Foster City, CA) were used to 
synthesize cDNA; 200 ng of RNA was used per synthesis reaction.  RT-PCR was 
performed using the iQ5 (Bio-Rad) and the iQ SYBR Green Supermix (Bio-Rad).  
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Triplicate reactions were performed in a mixture consisting of a 25 µl volume solution 
containing SYBR Green supermix PCR buffer (Bio-Rad; 2x reaction buffer with dNTPs, 
iTaq DNA polymerase, 6 mm MgCl2, SYBR Green I, fluorescein, and stabilizers), 1 µl of 
synthesized cDNA, 400 nM of each primer, and sterile water.  Forty cycles of 
denaturation (95 oC, 15 s), annealing (60 oC, 30 s), and elongation (72 oC, 10 s) were 
performed.  Fluorescence was detected at the end of every 72 oC extension phase.  
Melting curve analysis was done to exclude contamination by non-specific PCR products. 
 
Statistical Analysis 
For protein values, statistical differences were determined by one-way ANOVA, 
SPSS 19.0 software (IBM, Armonk, New York).  A level of p < 0.05 was considered 
significant.  For mRNA values, fold change was calculated, and statistical significance 
was set at a fold change of 2 or greater. 
 
Results 
FABP Protein Analysis 
As shown in Figure 11, when both age groups were combined, AA malignant 
(AAM) had higher FABP5 protein relative to AA normal (AAN; p=0.030) and CA 
malignant (CAM; p=0.012).  No differences were observed when the data were split by 
age.  
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Figure 11.  FABP5 Protein Levels, All Ages.  A. Graphed results.  AAM had higher 
FABP5 protein relative to AAN (p=0.030) and CAM (p=0.012).  IDV- integrated density 
values.  B. Representative Western blots of FABP5 and cytokeratin 18 internal standard 
from both age groups. 
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Figure 12 shows the results of FABP3 protein analysis.  When both age groups were 
combined, FABP3 (15 kDa) was significantly higher in CAM relative to CA normal 
(CAN; p=0.028), and in AAM relative to AAN (p<0.001) and to CAM (p=0.012).  
FABP3 (18 kDa) was significantly higher in CAM relative to CAN (p<0.001) and in 
AAM relative to AAN (p<0.001).  FABP3 (total) was significantly higher in CAM 
relative to CAN (p=0.006), and in AAM relative to AAN (p<0.001) and to CAM 
(p=0.017).  For ages below 50, FABP3 (15 kDa) was significantly higher in AAM 
relative to AAN (p=0.001) and to CAM (0.045).  FABP3 (18 kDa) was significantly 
higher in AAM relative to AAN (p=0.001).  FABP3 (total) was significantly higher in 
AAM relative to AAN (p=0.001) and to CAM (p=0.045).  For ages 50 and older, FABP3 
(15 kDa) was significantly higher in CAM relative to CAN (p=0.028) and in AAM 
relative to AAN (p<0.001).  FABP3 (18 kDa) and FABP3 (total) were also significantly 
higher in CAM relative to CAN (p<0.001 and p=0.006, respectively), and in AAM 
relative to AAN (p<0.001 for both). 
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Figure 12.  FABP3 Protein Levels, All Ages and Split By Age Group.  A-C. Graphed 
results.  A. All ages- FABP3 (15 kDa) was higher in CAM and AAM relative to normal 
(p=0.028 and p<0.001, respectively), and in AAM relative to CAM (p=0.012).  FABP3 
(18 kDa) was higher in CAM and AAM relative to normal (p<0.001 for both).  FABP3 
(total) was higher in CAM and AAM relative to normal (p=0.006 and p<0.001, 
respectively), and in AAM relative to CAM (p=0.017).  B. Ages below 50- FABP3 (15 
kDa) was higher in AAM relative to AAN (p=0.001) and to CAM (0.045).  FABP3 (18 
kDa) was higher in AAM relative to AAN (p=0.001). FABP3 (total) was higher in AAM 
relative to AAN (p=0.001) and to CAM (p=0.045).  C. Ages 50 and older- FABP3 (15 
kDa) was higher in CAM and AAM relative to normal (p=0.028 and p<0.001, 
respectively).  FABP3 (18 kDa) and FABP3 (total) were also higher in CAM relative to 
CAN (p<0.001 and p=0.006, respectively), and in AAM relative to AAN (p<0.001 for 
both).  D. Representative Western blots of FABP3 and cytokeratin 18 internal standard 
from both age groups. 
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FABP Messenger RNA Analysis 
As shown in Figure 13, in ages below 50, levels of both FABPs were not 
significantly different between CAM and AAM.  In ages 50 and older, FABP3 mRNA 
was significantly higher in CAM relative to AAM (87-fold).  Conversely, FABP5 mRNA 
was significantly higher in AAM relative to CAM (9-fold). 
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Figure 13.  FABP Messenger RNA Levels, Split by Age Group.  A. FABP mRNA levels, 
ages below 50.  Levels of both FABPs were not significantly different between CAM and 
AAM.  B. FABP mRNA levels, ages 50 and older.  FABP3 mRNA was higher in CAM 
relative to AAM (87-fold).  FABP5 mRNA was higher in AAM relative to CAM (9-fold). 
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Discussion 
Prior to initiation of the study, we hypothesized that levels of FABP5 protein 
would be significantly higher in malignant tissues, and particularly in AAM tissues 
relative to CAM tissues, which would reflect increased tumor aggressiveness.  Regarding 
FABP3 protein and mRNA levels, we hypothesized that levels would be significantly 
higher in normal tissues, and particularly in CAN tissues relative to AAN tissues, due to 
differences in lactation rates between the ethnic groups.  Our findings for FABP5 were as 
hypothesized; however findings for FABP3 differed from those hypothesized. 
Analysis of FABP5 protein levels showed that in AA tissues, malignant samples 
had significantly higher FABP5 protein compared to normal samples.  Moreover, the 
AAM samples had higher FABP5 relative to CAM, indicative of increased tumor 
aggressiveness and metastatic potential in the former.  Notably, the CAM and CAN 
samples had similarly low levels of FABP5 protein, consistent with decreased 
aggressiveness.  RNA analysis in ages below 50 showed no significant FABP5 difference 
between AAM and CAM; however, analysis in ages 50 and older showed that AAM 
samples expressed higher levels of FABP5 mRNA relative to CAM, again, indicative of 
increased tumor aggressiveness in this group. 
FABP3 protein was expressed in 3 bands- 14, 15, and 18 kDa.  A recently 
published study analyzing FABP3 protein levels in the mouse heart indicated a similar 
immunoprecipitation banding pattern [Lewis et al., 2010].  The 14 kDa and 15 kDa bands 
were merged in some samples, and thus we analyzed the total of these two bands 
(referred to as 15 kDa).  The 18 kDa band represents modified FABP3, likely tyrosine-
phosphorylated, as predicted in the literature [Nielsen and Spener, 1993].  In this study, 
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increased FABP3 was consistently associated with malignancy, in both CA and AA 
samples, and in both age groups; to our knowledge, this association has not been 
previously described in the literature.  There did not appear to be a difference in this trend 
among the various molecular weights.  Of note, FABP3 was higher in AAM relative to 
CAM in ages less than 50 (14,15 kDa, total).  When age was not used to split the data, 
FABP3 was also higher in AAM relative to CAM (14,15 kDa, total).  RNA analysis 
indicated that CAM tissues expressed much higher levels of FABP3 mRNA relative to 
AAM.   
The FABP3 mRNA levels do not reflect protein levels, as in the FABP5 analysis; 
the significance of this is yet unknown.  In a recent study which attempted to define the 
genetic profile of tumors that were at high risk of local recurrence after breast conserving 
therapy, the top scoring gene was fabp3 [Kreike et al., 2006].  This supports our findings 
that increased expression of FABP3 is highly associated with the malignant state, in 
addition to being associated with differentiation as supported by several studies in the 
literature. 
Thus, this study demonstrates that increased FABP3 and FABP5 are both 
associated with breast malignancy, and that there is differential expression of these 
proteins in AA and CA tissues.  This finding is particularly significant for FABP3, as 
previous literature generally described this protein as a tumor suppressor and as 
decreased in the cancer state.  Both proteins are increased in AAM patients relative to 
AAN and CAM counterparts.  In ages 50 and older, significant mRNA changes are also 
seen, showing increased FABP5 mRNA in AAM relative to CAM and thus increased 
aggressiveness and metastatic potential.  Further work involves determining the post-
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translational modifications present in the FABP3 protein expressed in the tissue samples, 
and further elucidating the FABP3 signaling pathway.  Clarification of the function and 
signaling mechanisms of FABPs 3 and 5 would aid in a better understanding of their role 
in the breast cancer health disparity. 
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CHAPTER FOUR 
 
OVERALL DISCUSSION 
 
 
Role of FABPs in Breast Tissue 
Our studies have shown that, regardless of age group, FABP3 protein is more 
highly expressed in malignant breast tissues, relative to normal tissues.  In ages below 50, 
FABP3 protein is more highly expressed in AAM tissues relative to CAM tissues.  This 
finding is a new one, in light of previous studies showing that FABP3 mRNA and protein 
are decreased in malignant breast tissues [Hertzel and Bernlohr, 2000; Huynh et al., 
1996].  In a clinical study, which attempted to define the genetic profile of breast 
tumors at high risk of recurrence after breast conserving therapy, the top scoring 
gene was fabp3 [Kreike et al., 2006].  Thus far, this study is the only published study, in 
addition to our studies, regarding FABP3 and increased risk of breast carcinogenesis.  
Furthermore, our study is the first, to our knowledge, to demonstrate that increased 
FABP3 protein levels are associated with malignancy, in addition to the existing 
association of increased FABP3 levels with differentiation.  It is possible that FABP3 has 
protective effects in the normal state, as repeatedly demonstrated in the literature, and 
then in the malignant state, is markedly upregulated in an attempt to halt cancer 
progression through its signaling effects.  To determine if FABP3 expression in the breast 
is higher in pregnancy or in the malignant state, one could sample breast tissue while 
women are pregnant and/or lactating; however, this would obviously be unethical. We 
were also able to see that FABP3 is expressed in an 18 kDa form in addition to the 15 
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kDa form.  A precedent for this finding was seen in the literature, in a study of FABP3 
found in mouse cardiac tissue [Lewis et al., 2010].  The 18 kDa form may be tyrosine-
phosphorylated, as predicted in the literature [Nielsen and Spener, 1993], and may relate 
to proper FABP3 signaling and function.  Both forms of FABP3 are increased in the 
malignant state.  When looking at mRNA levels, we found that in ages below 50, FABP3 
was not significantly different between CAM and AAM patients.  However, in ages 50 
and older, FABP3 mRNA had almost 90-fold greater expression in CAM relative to 
AAM.  This is interesting given that as it relates to protein expression, FABP3 is 
significantly higher in AAM relative to CAM in ages below 50, and not significantly 
different between AAM and CAM in ages 50 and older.  The significance of this is as yet 
unknown.  It could be that the FABP3 mRNA in AAM tissues is translated or degraded at 
a higher rate, thus causing the mRNA to be significantly decreased.   
In AA patients, FABP5 protein is more highly expressed in malignant tissues; 
however, this does not hold true in CA patients.  Additionally, FABP5 is more highly 
expressed in AAM relative to CAM.  For ages 50 and older, the FABP5 mRNA levels are 
consistent with the protein findings; levels in AAM are 9-fold higher than in CAM.   
Since FABP5 is associated with metastasis and carcinogenesis [Jing et al., 2000], this 
implies greater aggressiveness of the AA tumors. 
 
Role of IGF-II and PRL in Breast Differentiation and 
Regulation of FABPs 
Studies of two untreated ER negative normal breast epithelial cell lines, MCF10A 
and AG11132, demonstrated that the CA MCF10A cell line had significantly higher 
levels of FABP3 and FABP5 protein relative to the AA AG11132 cell line.  FABP5 
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mRNA was also significantly higher in MCF10A cells, relative to AG11132 cells.  
However, FABP3 mRNA was undetectable in MCF10A cells, and expressed at very low 
levels in AG11132 cells.  This may indicate that FABP5 has a greater role in normal cell 
functioning which includes intracellular fatty acid transport, while FABP3 may have a 
more differentiation-specific role (i.e., FABP3 mRNA levels only increase when the cells 
receive a differentiation stimulus).  Untreated MCF10A cells also had higher levels of 
PRL and IGF-II protein relative to AG11132 cells.  Conversely, the mRNA levels of 
these two proteins were increased in AG11132 cells, with IGF-II mRNA levels being 
over 40-fold higher.  This finding is consistent with previous results from our laboratory, 
which demonstrated higher IGF-II mRNA levels in AA normal breast tissue relative to 
CA normal tissue, with the difference most pronounced in women below 45 years of age 
[Kalla Singh et al., 2010].   
Studies of PRL-treated MCF10A and AG11132 cell lines demonstrated that 
FABP3 protein increased in response to PRL treatment in the AG11132 cell line, and 
remained steady in the MCF10A cell line with a decrease at highest treatment 
concentration.  This was mostly likely due to differences in PRLR and initial FABP3 
protein levels between the two cell lines.  MCF10A cells expressed the long form of 
PRLR, and had high levels of FABP3 protein in the untreated state, while AG11132 cells 
did not express the PRLR long form, and had significantly lower levels of FABP3 
protein.  In both cell lines, PRL treatment resulted in decrease in FABP5 protein, which is 
associated with decreased metastatic potential, and was in accordance with previous 
findings in the literature.  Response of IGF-II to PRL signaling differed somewhat 
between the two cell lines.  In the MCF10A cell line, PRL treatment resulted in increases 
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in IGF-II mRNA. This was to be expected as IGF-II has been reported to mediate PRL’s 
differentiation effects [Brisken et al., 2002].  However, in the AG1132 cell line, PRL 
treatment resulted in increased IGF-II mRNA at lower concentrations, and decreased 
IGF-II mRNA at higher concentrations. Additionally, maximal levels of FABP3 were 
associated with low IGF-II mRNA levels in this cell line. 
Thus, it can be seen that PRL treatment of both cell lines induced a favorable 
profile as it relates to decreased risk of carcinogenesis—increased or maintained 
protective FABP3 and decreased FABP5, which is associated with metastasis.  
Interestingly, in AG11132 cells, IGF-II mRNA levels only increased at low PRL 
concentration, while FABP3 protein levels increased with increasing PRL concentration.  
This indicates that IGF-II may mediate increased/maintained FABP3 protein levels in 
MCF10A cells, but not in AG11132 cells, and that PRL signaling may not involve IGF-II 
in the latter cell line at higher treatment concentrations.  Though IGF-II has been reported 
to mediate PRL’s differentiation effects through upregulation of cyclin D1 [Brisken et al., 
2002; Hovey et al., 2003], there is some evidence that IGF-II may not be required for 
these effects in all cases.  For example, Carver and Schuler [2008] demonstrated that in 
the MCF-7 breast cancer cell line, PRL was able to induce cyclin D1 expression prior to 
upregulation of IGF-II transcript levels, suggesting that though PRL caused IGF-II 
increase, this was not required for signaling.  
 
Conclusions and Future Directions 
In summary, we have seen that though FABP3 is associated with differentiation, 
both FABP3 and FABP5 proteins increase in the malignant state, and that AAM breast 
71 
tissues express higher levels of these proteins, relative to CAM tissues. In ages above 50, 
the FABP3 mRNA is significantly increased in CAM, pointing to a possible greater 
protection, or reserve against carcinogenesis, while the FABP5 mRNA is significantly 
increased in AAM, pointing to greater tumor aggressiveness. Cell studies demonstrate 
that FABP3 and FABP5 are expressed in normal mammary epithelial cells, and that 
treatment of these cells with PRL causes increased/maintained FABP3 levels, with the 
AA cell line showing a more robust response likely due to decreased initial FABP3 and 
PRLR levels.  If the finding of lower PRLR levels were to hold true in AA breast tissue, 
it would provide a rationale for decreased protection against carcinogenesis, as higher 
levels of PRL would be required to induce protective differentiation changes in the 
breast.  In both cell lines, decreased FABP5 is also seen, which may be protective against 
carcinogenesis.  In the CA cell line, levels of FABP protein appear to be regulated by 
increased IGF-II, while in the AA cell line, IGF-II appears to only be involved at lower 
treatment concentrations.   
The demonstration that PRL treatment of AG11132 cells, normal mammary 
epithelial cells with low levels of FABP3, may simulate the protective effect of 
pregnancy, and cause a protective increase in FABP3, may be utilized for protective 
short-term pretreatment of human breast tissue in the future.   Russo and colleagues 
[2005] have demonstrated that short-term pretreatment of breast tissue with human 
chorionic gonadotropin is able to induce a protective genomic signature, mimicking that 
of breast tissue that has undergone pregnancy and lactation-induced differentiation.  
Further PRL treatment experiments in normal mammary epithelial cell lines and animal 
breast tissue may validate a protective pretreatment effect at the genetic level, which 
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would include increased FABP3 expression.  In the breast cancer state, PRL levels are 
dysregulated, and high levels are associated with increased proliferation [Swaminathan et 
al., 2008].  However, increasing PRL levels in normal breast cells for short-term 
treatment should not have the same effect.  As aforementioned, in both premenopausal 
and postmenopausal women, PRL levels are markedly upregulated after the first 
pregnancy, followed by a long-lasting reduction in levels, which is protective against 
future carcinogenesis [Tworoger and Hankinson, 2008].   
To be able to apply our initial findings to the larger population, further studies are 
needed.  Some of these studies would include: determining the post-transcriptional 
modifications present in FABP3 protein in breast tissues from AA and CA women, 
measuring PRLR levels in AA and CA breast tissues, PRL treatment of other CA and AA 
normal cell lines to determine if the findings above are consistent, and elucidating the 
FABP3 nuclear signaling pathway in further detail.  At present, we can state that our 
studies have been able to preliminarily elucidate the differences in FABP3 and FABP5 
expression between AA and CA breast tissues and cell lines, as well as differences in the 
responses of the cell lines to PRL treatment, and have shed light on possible biological 
mechanisms undergirding the breast cancer health disparity.   
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